Zeo ScientifiX, Inc. (ZEOX)

OTCMKTS · Delayed Price · Currency is USD
2.040
+0.115 (5.97%)
Mar 6, 2026, 2:05 PM EST
-16.73%
Market Cap 14.88M
Revenue (ttm) 5.20M
Net Income (ttm) -5.52M
Shares Out 7.73M
EPS (ttm) -0.86
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 200
Average Volume 7,702
Open 2.040
Previous Close 1.925
Day's Range 2.040 - 2.050
52-Week Range 1.200 - 3.320
Beta 3.95
RSI 42.89
Earnings Date Mar 17, 2026

About Zeo ScientifiX

Zeo ScientifiX, Inc., a clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases and regenerative medicines. Its lead product candidate is Zofin, an acellular biologic therapeutic derived from perinatal sources, which is in Phase I/II clinical trial to treat COVID-19, chronic obstructive pulmonary disease, osteoarthritis,and traumatic brain injury. The company also provides Patient Pure X, an autologous biologic, that helps reduce inflammation and promote tissue h... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 20
Stock Exchange OTCMKTS
Ticker Symbol ZEOX
Full Company Profile

Financial Performance

In fiscal year 2025, Zeo ScientifiX's revenue was $5.20 million, an increase of 12.53% compared to the previous year's $4.62 million. Losses were -$5.52 million, 17.3% more than in 2024.

Financial Statements

News

There is no news available yet.